Redbiotec, a Swiss biotechnology company, develops immunotherapies against Herpes and cancer.
Our therapies are based on best-in-class proteins and microorganisms.
Track record of Redbiotec:
- Deals closed with pharma companies in U.S., Asia and Europe (including Switzerland)
- Trade sale of spin-off Redvax to Pfizer (press release) for its CMV vaccine program and a further undiclosed program.
- Internationally recognized scientists as scientific advisors
- Engineering and production of >100 novel proteins and protein complexes
- First company having successfully developed stable CMV pentamer at >95% purity